ATM kinase activity modulates cFLIP protein levels: Potential interplay between DNA damage signalling and TRAIL-induced apoptosis

Carcinogenesis

Volumn 31, Issue 11, 2010, Pages 1956-1963

  Stagni, Venturina ^a,b   Mingardi, Michele ^a   Santini, Simonetta ^a,b   Giaccari, Danilo ^a   Barilà, Daniela ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; FLICE INHIBITORY PROTEIN; FLUOROURACIL; MUTANT PROTEIN; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; ZINOSTATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CATALYSIS; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SENSITIZATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; DOWN-REGULATION; FLUOROURACIL; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIVER NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION; ZINOSTATIN;

EID: 78149257662     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq193     Document Type: Article

References (43)

1. Wiley,S.R. et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-682.
2. Walczak,H. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5, 157-163.
3. Dyer,M.J. et al. (2007) Barriers to effective TRAIL-targeted therapy of malignancy. J. Clin. Oncol., 25, 4505-4506.
4. Ashkenazi,A. et al. (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest., 118, 1979-1990.
5. Falschlehner,C. et al. (2007) TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol., 39, 1462-1475.
6. Yu,J.W. et al. (2008) FLIP and death effector domain family. Oncogene, 27, 6216-6227.
7. Dutton,A. et al. (2004) Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fasmediated death. Proc. Natl Acad. Sci. USA, 101, 6611-6616.
8. Mathas,S. et al. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J. Exp. Med., 199, 1041-1052.
9. Ganten,T.M. et al. (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ., 11 (suppl. 1), S86-S96.
10. Ganten,T.M. et al. (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res., 12, 2640-2646.
11. Thome,M. et al. (2001) Regulation of lymphocyte proliferation and death by FLIP. Nat. Rev. Immunol., 1, 50-58.
12. Petak,I. et al. (2001) Shared pathways; death receptors and cytotoxic drugs in cancer therapy. Pathol. Oncol. Res., 7, 96-106.
13. Safa,A.R. et al. (2008) Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets, 8, 37-46.
14. Stagni,V. et al. (2008) ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood, 111, 829-837.
15. Biton,S. et al. (2006) Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuronlike cells. J. Biol. Chem., 281, 17482-17491.
16. Brummelkamp,T. et al. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550-553.
17. Salvat,C. et al. (2000) Molecular characterization of the thermosensitive E1 ubiquitin-activating enzyme cell mutant A31N-ts20. Eur. J. Biochem., 267, 3712-3722.
18. Barilà,D. et al. (2003) Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol. Cell. Biol., 23, 2790-2799.
19. Fukazawa,T. et al. (2001) Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene, 20, 5225-5231.
20. Galligan,L. et al. (2005) Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol. Cancer Ther., 4, 2026-2036.
21. Banin,S. et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science, 281, 1674-1677.
22. Khanna,K.K. et al. (1998) ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet., 20, 398-400.
23. Hickson,I. et al. (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res., 64, 9152-9159.
24. Inoue,S. et al. (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ., 11 (suppl. 2), S193-S206.
25. Fulda,S. (2008) Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets, 8, 132-140.
26. Sayers,T.J. et al. (2003) The proteasome inhibitor PS-341 sensitizes cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 102, 303-310.
27. Anan,A. et al. (2005) A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome. Hepatology, 42, 527-529.
28. Koschny,R. et al. (2007) TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 45, 649-658.
29. Zhao,X. et al. (2008) Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expresssion profiling study with implications for potential combination therapies. Leuk. Res., 32, 275-285.
30. Ivanov,V.N. et al. (2009) Inhibition of Ataxia Telangiectasia Mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res., 69, 3510-3519.
31. Abedini,M.R. et al. (2008) Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res., 68, 4511-4517.
32. Verbrugge,I. et al. (2010) Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ., 17, 551-561.
33. Longley,D.B. et al. (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene, 25, 838-848.
34. White,S.J. et al. (2007) Doxorubicin generates a pro-apoptotic phenotype by phosphorylation on EF-2. Free Radic. Biol. Med., 43, 1313-1321.
35. Taylor,A. et al. (2002) Ubiquitination capabilities in response to neocarzinostatin and H(2)O(2) stress in cell lines from patients with ataxiatelangiectasia. Oncogene, 21, 4363-4373.
36. Matsuoka,S. et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science, 316, 1160-1166.
37. Mu,J.-J. et al. (2007) A proteomic analysis of Ataxia Telangiectasiamutated (ATM/ATM-Rad3-related (ATR) substrates identifies the ubiquitin proteasome system as a regulator for DNA damage checkpoints. J. Biol. Chem., 282, 17330-17334.
38. Wu,Z.H. et al. (2006) Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science, 311, 1141-1146.
39. Dornan,D. et al. (2006) ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science, 313, 1122-1126.
40. Maya,R. et al. (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev., 15, 1067-1077.
41. Chang,L. et al. (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell, 124, 601-613.
42. Kamer,I. et al. (2005) Proapoptotic BID is an ATM effector in the DNAdamage response. Cell, 122, 593-603.
43. Zinkel,S.S. et al. (2005) A role for proapoptotic BID in the DNA-damage response. Cell, 122, 579-591.